We discuss a novel mechanism of action for the treatment of diabetic macular edema and neovascular AMD with Phase I/II trial results Dr. Raj Maturi, Midwest Eye Institute, Indiana University School of Medicine.

We review lesion progression in the eighteen month data with Roger Goldberg, MD, MBA of Bay Area Retina Associates, Walnut Creek, California.

We discuss the role that clinicians can play in fostering innovation in the retinal pharmacotherapy space with Dr. Eliot Lazar.

We discuss the 12 month results of the Phase I Davio Trial of an innovative TKI agent for the sustained treatment of neovascular AMD with Dr. Rishi Singh, Professor of Ophthalmology, Cole Eye Insitute, President, Cleveland Cllinic-Martin Hospital, Stuart, Florida.

We discuss treat and extend versus alternate dosing strategies to treat center involving diabetic macular edema with Dr. Varun Chaudhary, Chief of Ophthalmology, Hamilton Regional Eye Center and Professor, McMaster University.

We discuss the role of IOP pressure elevation following intravitreal anti-VEGF therapy with Parnian Arjmand, MD, MSC, FCSRS of the Toronto Retina Institute.

We discuss real world experience about faricimab with Dr. Carl Danzig of Pompano Beach, Florida.

We discuss new treatment options and clinical trials for radiation retinopathy with Prithvi Mruthyunjaya MD Professor of Ophthalmology, Stanford Medical School, Director of Ocular Oncology, Byers Eye Institute.

We discuss new developments in gene therapy for inherited retinal diseases with Sue Washer, President and CEO of AGTC.

We discuss a novel strategy using RNA anti sense technology for treating geographic atrophy with Dr. Nik London,  San Diego, California.